Outcomes for Bacterial Meningitis in Patients With Multiple Myeloma
Researchers sought to determine the outcomes for patients with multiple myeloma who develop bacterial meningitis.
Multiple Myeloma
Measuring Circulating Tumor Cells at Diagnosis Can Improve Risk Stratification in Multiple Myeloma
Circulating tumor cell levels were an independent predictor of progression-free survival and overall survival.
Ocular Toxicity Appears Common With Belantamab Mafodotin in Advanced Multiple Myeloma
Researchers sought to determine whether ocular toxicity occurred in a significant number of patients with multiple myeloma treated with belantamab mafodotin.
A-Fib Linked to Worse Hospital Outcomes in Multiple Myeloma
In stratified analysis, odds of all-cause mortality, hospital stay of more than five days higher for MM patients not using anticoagulation.
Microvesicles and Possible Implications for Patients With Multiple Myeloma
Researchers sought to determine the implications of plasma levels of microvesicles in patients with multiple myeloma.
CD24 Expression on Plasma Cells Is a Prognostic Marker for Survival in Multiple Myeloma
Researchers sought to determine whether elevated CD24 expression on plasma cells was a prognostic factor in multiple myeloma.
Comorbidity Treatment Regimens a Contributor to Nonadherence to Oral Multiple Myeloma Treatment Regimens
An analysis of patient databases sought to determine which factors may contribute to poor adherence to oral anticancer agents among patients with MM.
Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma
Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.
Evusheld Appears Less Effective Against Omicron for Patients With Blood Cancer
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
Racial Disparities Seen in US Food and Drug Administration Drug Approval Trials in Multiple Myeloma
Researchers sought to determine whether patients were equally represented along designated racial groups in FDA drug trails for multiple myeloma.
- Loading...
Loading...
Next post in Multiple Myeloma
Loading... 
Loading...